US Patent

US10039745 — Enalapril formulations

Formulation · Assigned to Silvergate Pharmaceuticals Inc · Expires 2036-03-25 · 10y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable enalapril oral liquid formulations for treating hypertension, heart failure, and asymptomatic left ventricular dysfunction.

USPTO Abstract

Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

Drugs covered by this patent

Patent Metadata

Patent number
US10039745
Jurisdiction
US
Classification
Formulation
Expires
2036-03-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Silvergate Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.